Tag: operations

ZEELAND, Mich., July 25, 2025 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today reported financial results for the three and six months ended June 30, 2025.

With a production budget that surpasses Squid Game Season 1, Trigger emerges as Netflix’s next high-stakes Korean mega-production

Major Offshore Acreage Expansion Creates New Growth Platform in the Gulf of Thailand

The global space debris monitoring and removal market, valued at USD 1.05 billion in 2024, is set to reach USD 2.05 billion by 2033, growing at a 7.8% CAGR. Driven by increased satellite deployments and demand for advanced debris technologies, the market supports sustainability and risk mitigation in space operations.

SHENZHEN, China, July 25, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that it is exploring the integration of emerging technologies, particularly quantum computing, into its existing operations. With its expertise in customer engagement and robust data ecosystem, Aurora Mobile believes quantum computing will be a driving force in its future growth and innovation.

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²